Here is the design of a clinical trial:

Official Title: Safety and Efficacy of PG102P for the coNtrol of prUritus in Patients underGoing Hemodialysis (SNUG Trial): Study Protocol for a Randomized Control Trial

Included conditions:
- Uremic Pruritus

Study Armgroups:
- {'label': 'a treatment group', 'type': 'EXPERIMENTAL', 'description': 'PG102P 1.5 g/day', 'interventionNames': ['Drug: PG102P']}
- {'label': 'a control group', 'type': 'PLACEBO_COMPARATOR', 'description': 'placebo', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'PG102P', 'description': 'Daily dose of 1.5g', 'armGroupLabels': ['a treatment group']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Daily dose of placebo', 'armGroupLabels': ['a control group']}

Primary Outcomes:
- {'measure': 'VAS change from baseline', 'description': 'The primary endpoint is the change in VAS', 'timeFrame': 'the change in VAS between visit 2 (week 0) and visits 3, 4, 5, and 6 (weeks 2, 4, 8, 10)'}

Please estimate the sample size based on the assumption: 
0.9 power, two-sided, 0.05 alpha, 30% dropout rate
Sample size calculations
        The enrolled participants will be randomly divided into two groups by at a 1:1 ratio. Under the assumption of 2.1âcm (with a pooled standard deviation of 2.4âcm) in the mean change difference in VAS values between the PG102P and placebo groups in a preceding pilot study with 0.9 of power, two-sided, and 0.05 of alpha, 28 participants will be allocated to each group. Considering a dropout rate of 30%, 80 participants will be needed (40 participants per group).